MAP2K7 and cancer: Importantly, the KRAS-mutant cancer cells independent of KRAS function, driven by mesenchymal reprogramming (high EMT gene signatures)2,16, exhibited significantly greater resistance to various MEK inhibitors (Fig. 1c).